Cardiovascular Drug Development Surges with Innovative Therapies and Fierce Market Competition.

he field of cardiovascular drug development is undergoing a dynamic resurgence, fueled by new therapeutic breakthroughs and increasing investment. Recent approvals, major funding milestones, and advancements in gene and RNA-based treatments are signaling a new chapter in the fight against the world’s leading cause of death.

One of the most notable developments is the approval of BridgeBio’s Attruby for transthyretin amyloid cardiomyopathy (ATTR-CM) in November 2024. Once considered a terminal condition, ATTR-CM now has two FDA-approved therapies—Pfizer’s tafamidis, marketed as Vyndaqel and Vyndamax, approved in 2019, and BridgeBio’s recent entrant, Attruby. A third treatment may soon join the lineup: Alnylam’s Amvuttra (vutrisiran), an RNA interference (RNAi) therapy already approved for polyneuropathy in hereditary ATTR, is under FDA review for ATTR-CM with a decision expected by March 23.

Also making strides in this space are AstraZeneca and Ionis Pharmaceuticals with Wainua (eplontersen), an antisense RNA therapy. Wainua, currently approved for hereditary ATTR amyloidosis, is undergoing a Phase III study (CARDIO-TTRansform) with results anticipated in 2026. The global transthyretin amyloidosis treatment market is forecasted to reach $9.35 billion by 2030, making this a highly competitive field.

Beyond ATTR-CM, GLP-1 receptor agonists—best known for their role in treating diabetes and obesity—are showing significant cardiovascular benefits. In March 2024, the FDA expanded the label for Novo Nordisk’s Wegovy (semaglutide) to include reduced cardiovascular risk in overweight patients. Eli Lilly’s tirzepatide, sold under Mounjaro and Zepbound, also demonstrated efficacy in heart failure with preserved ejection fraction. Companies like Amgen and Structure Therapeutics are also exploring cardiovascular applications for GLP-1s.

Gene therapy is another rapidly evolving frontier. Firms such as Renova Therapeutics, XyloCor, and Tenaya Therapeutics are advancing therapies targeting congestive heart failure, chronic refractory angina, and hypertrophic cardiomyopathy. Encouraging early results include Rocket Pharmaceuticals’ Phase I clinical benefit and Lexeo Therapeutics’ progress in Friedreich’s ataxia cardiomyopathy.

With the global cardiovascular drug market expected to grow from $150 billion in 2024 to $207 billion by 2033, companies large and small are intensifying efforts to capitalize on this high-stakes, high-impact sector.

Source: https://www.biospace.com/drug-development/deep-dive-cardiovascular-disease-back-in-the-spotlight

This is non-financial/medical advice and made using AI so could be wrong.